|
| Index | - | P/E | - | EPS (ttm) | -0.95 | Insider Own | 12.00% | Shs Outstand | 8.11M | Perf Week | -3.76% |
| Market Cap | 336.68M | Forward P/E | 141.96 | EPS next Y | 0.28 | Insider Trans | -0.20% | Shs Float | 3.11M | Perf Month | -4.42% |
| Income | -7.40M | PEG | - | EPS next Q | -0.26 | Inst Own | 4.10% | Short Float / Ratio | 2.83% / 7.28 | Perf Quarter | 2.92% |
| Sales | 37.60M | P/S | 8.95 | EPS this Y | -42.00% | Inst Trans | 28.02% | Short Interest | 0.09M | Perf Half Y | 28.93% |
| Book/sh | 5.61 | P/B | 7.09 | EPS next Y | 122.00% | ROA | -15.60% | Target Price | 60.00 | Perf Year | 45.85% |
| Cash/sh | 1.22 | P/C | 32.69 | EPS next 5Y | - | ROE | -19.70% | 52W Range | 17.41 - 49.50 | Perf YTD | -11.56% |
| Dividend | - | P/FCF | - | EPS past 5Y | -11.60% | ROI | -24.10% | 52W High | -18.71% | Beta | 1.84 |
| Dividend % | - | Quick Ratio | 1.80 | Sales past 5Y | 34.40% | Gross Margin | 87.30% | 52W Low | 131.13% | ATR | 1.72 |
| Employees | 63 | Current Ratio | 2.20 | Sales Q/Q | 124.10% | Oper. Margin | -32.00% | RSI (14) | 43.16 | Volatility | 5.54% 3.76% |
| Optionable | No | Debt/Eq | 0.00 | EPS Q/Q | 32.50% | Profit Margin | -18.50% | Rel Volume | 1.23 | Prev Close | 39.75 |
| Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | Mar 20 AMC | Payout | - | Avg Volume | 12.10K | Price | 40.24 |
| Recom | 2.00 | SMA20 | -2.71% | SMA50 | -5.90% | SMA200 | 21.32% | Volume | 3,744 | Change | 1.23% |
 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biakos Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biakos Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biakos Antimicrobial Skin and Wound Irrigation Solution. The company also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a single layer sheet of amnion tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite